Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy
ConclusionOur findings confirm pericardial effusion as a relatively frequent side effect of immunotherapy in NSCLC. Clinicians should be aware of this specific toxicity in patients with metastatic NSCLC receiving immunotherapy and refer to a cardiologist for a multidisciplinary approach.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Cardiology | Chemotherapy | Drugs & Pharmacology | Heart | Immunotherapy | Lung Cancer | Myocarditis | Non-Small Cell Lung Cancer | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology